| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4028466 | Ophthalmology | 2008 | 6 Pages |
Abstract
Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Sang Woo MD, Byung Jin MD, Eung Kweon MD, PhD, Hungwon MD, Tae-im MD,